Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Vitamin C for COVID-19: real-time meta analysis of 52 studies
Covid Analysis, October 3, 2022, DRAFT
https://c19early.com/cmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Su -135% 2.35 [0.67-8.27] progression n/a n/a Improvement, RR [CI] Treatment Control Su -34% 1.34 [1.02-1.73] no improv. n/a n/a Thomas (RCT) -204% 3.04 [0.13-72.9] death 1/48 0/50 Thomas (RCT) 31% 0.69 [0.12-3.98] hosp. 2/48 3/50 Thomas (RCT) 18% 0.82 [0.63-1.07] recov. time 48 (n) 50 (n) Zhao (PSM) 72% 0.28 [0.08-0.93] progression 4/55 12/55 Zhao (PSM) -8% 1.08 [0.64-1.80] viral time 55 (n) 55 (n) Ried (RCT) 31% 0.69 [0.54-0.89] no recov. 69/162 46/75 Usanma Koban 33% 0.67 [0.07-5.38] viral+ 31 (n) 95 (n) Krishnan 31% 0.69 [0.47-0.92] death 40/79 52/73 Zhang (RCT) 50% 0.50 [0.20-1.50] death 6/27 11/29 ICU patients Zhang (RCT) 80% 0.20 [0.10-0.90] death 5/27 11/29 ICU patients Zhang (RCT) 50% 0.50 [0.20-1.80] death 6/27 10/29 ICU patients Zhang (RCT) 70% 0.30 [0.21-1.10] death 5/27 10/29 ICU patients Yüksel (ICU) 19% 0.81 [0.66-0.99] death 31/42 40/44 ICU patients Patel 29% 0.71 [0.43-1.14] death 22/96 26/80 Patel 16% 0.84 [0.52-1.36] death 15/30 16/27 Kumari (RCT) 36% 0.64 [0.26-1.55] death 7/75 11/75 Kumari (RCT) 20% 0.80 [0.40-1.59] ventilation 12/75 15/75 Kumari (RCT) 26% 0.74 [0.64-0.86] recov. time 75 (n) 75 (n) Kumari (RCT) 24% 0.76 [0.66-0.87] hosp. time 75 (n) 75 (n) Darban (RCT) 33% 0.67 [0.14-3.17] progression 2/10 3/10 ICU patients CT​2 Darban (RCT) 6% 0.94 [0.84-1.06] ICU 10 (n) 10 (n) ICU patients CT​2 Jang 51% 0.49 [0.23-1.01] no recov. 5/12 6/7 ECMO patients JamaliMo.. (RCT) 0% 1.00 [0.22-4.56] death 3/30 3/30 JamaliMo.. (RCT) -25% 1.25 [0.37-4.21] ventilation 5/30 4/30 JamaliMo.. (RCT) -31% 1.31 [1.03-1.66] hosp. time 30 (n) 30 (n) Gao 86% 0.14 [0.03-0.72] death 1/46 5/30 Hamidi-A.. (RCT) 44% 0.56 [0.20-1.51] death 5/40 9/40 CT​2 Hamidi-A.. (RCT) 38% 0.62 [0.45-0.86] hosp. time 40 (n) 40 (n) CT​2 Al Sulaiman (PSM) 15% 0.85 [0.61-1.12] death 46/142 59/142 Mulhem -32% 1.32 [1.07-1.62] death 157/794 359/2,425 Gadhiya -1% 1.01 [0.48-1.91] death 19/55 36/226 Hakamifard (RCT) 46% 0.54 [0.14-2.08] ICU 3/38 5/34 CT​2 Hakamifard (RCT) 1% 0.99 [0.91-1.07] hosp. time 38 (n) 34 (n) CT​2 Elhadi (ICU) -12% 1.12 [0.96-1.31] death 175/277 106/188 ICU patients Suna 21% 0.79 [0.44-1.41] death 17/153 24/170 Suna -2% 1.02 [0.46-2.24] ICU 11/153 12/170 Pourhoseingholi 13% 0.87 [0.63-1.19] death 54/199 285/2,269 Li (ICU) -11% 1.11 [0.79-1.54] death 7/8 19/24 ICU patients Vishnuram 54% 0.46 [0.24-0.86] death 164/8,634 10/241 Özgünay (ICU) 9% 0.91 [0.63-1.30] death 17/32 75/128 ICU patients Özgünay (ICU) -1% 1.01 [0.79-1.29] ventilation 23/32 91/128 ICU patients Tan 25% 0.75 [0.10-2.98] death/int. 1/46 14/115 CT​2 Tan 73% 0.27 [0.09-0.61] ARDS 7/46 41/115 CT​2 Zheng (PSM) -157% 2.57 [0.39-16.8] death 12/70 7/327 Zheng -169% 2.69 [0.91-7.89] death 12/70 7/327 Zheng (PSM) -35% 1.35 [0.88-2.08] no improv. 18/70 16/327 Zheng -32% 1.32 [0.93-1.82] no improv. 18/70 16/327 Simsek 44% 0.56 [0.23-1.35] death 6/58 15/81 Simsek 10% 0.90 [0.55-1.46] ICU 18/58 28/81 Shousha 94% 0.06 [0.01-0.37] death 22/340 31/207 Tehrani (RCT) 87% 0.13 [0.01-2.25] death 0/18 4/26 Tehrani (RCT) 18% 0.82 [0.60-1.13] hosp. time 18 (n) 26 (n) Majidi (DB RCT) 14% 0.86 [0.74-1.01] death 26/31 67/69 ICU patients Baguma -48% 1.48 [0.41-4.70] death 385 (n) 96 (n) Tu 83% 0.17 [0.08-0.35] death 8/116 26/64 Yang (RCT) 15% 0.85 [0.68-1.06] recov. time 10 (n) 10 (n) LD​3 Yang (RCT) 15% 0.85 [0.75-0.97] recov. time 10 (n) 10 (n) LD​3 Yang (RCT) 14% 0.86 [0.66-1.11] viral time 10 (n) 10 (n) LD​3 Yang (RCT) 19% 0.81 [0.68-0.96] viral time 10 (n) 10 (n) LD​3 Gavrielatou (ICU) 58% 0.42 [0.12-1.48] death 2/10 49/103 ICU patients Salehi (ICU) 10% 0.90 [0.65-1.25] death 22/40 52/85 ICU patients Coppock (RCT) 5% 0.95 [0.16-7.84] progression 4/44 2/22 Coppock (RCT) 50% 0.50 [0.16-1.33] no improv. 6/44 6/22 Coppock (RCT) 22% 0.78 [0.59-1.02] no disch. 31/44 20/22 Hess (PSW) 20% 0.80 [0.40-1.60] death 10/25 37/75 Hess (PSW) 40% 0.60 [0.28-1.00] ventilation 18/25 54/75 Hess (PSW) 50% 0.50 [0.20-0.90] ventilation 18/25 54/75 Hess (PSW) 27% 0.73 [0.41-1.04] ICU 22/25 63/75 Hess (PSW) 30% 0.70 [0.40-1.20] ICU 22/25 63/75 Zangeneh (ICU) 4% 0.96 [0.64-1.45] death n/a n/a ICU patients Izzo 41% 0.59 [0.50-0.69] recovery 869 (n) 521 (n) LONG COVID OT​1 CT​2 Izzo 68% 0.33 [0.19-0.57] recovery 869 (n) 521 (n) LONG COVID OT​1 CT​2 Fogleman (DB RCT) 4% 0.96 [0.65-1.40] recovery 32 (n) 34 (n) Kumar (DB RCT) 23% 0.77 [0.40-1.47] death 10/30 13/30 ICU patients Kumar (DB RCT) 21% 0.79 [0.43-1.44] ventilation 11/30 14/30 ICU patients Behera 18% 0.82 [0.45-1.57] cases case control Behera 29% 0.71 [0.40-1.26] cases case control Louca 0% 1.00 [0.97-1.04] cases Mahto -26% 1.26 [0.63-2.28] IgG+ 34/140 59/549 Holt -3% 1.03 [0.77-1.39] cases 49/1,580 397/13,647 Abdulateef 19% 0.81 [0.37-1.78] hosp. 8/132 22/295 Aldwihi 36% 0.64 [0.45-0.86] hosp. 142/505 95/233 Mohseni -44% 1.44 [1.22-1.71] cases 34/43 307/560 Nimer 25% 0.75 [0.54-1.04] hosp. 52/651 167/1,497 Nimer 17% 0.83 [0.62-1.09] severe case 66/651 194/1,497 Shehab 4% 0.96 [0.46-1.99] severe case 14/139 12/114 Loucera 28% 0.72 [0.58-0.88] death 840 (n) 15,128 (n) vitamin C COVID-19 outcomes c19early.com/c Oct 2022 1 OT: comparison with other treatment3 LD: comparison with low dose treatment 2 CT: study uses combined treatment Favors vitamin C Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit